Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
APLS

APLS - Apellis Pharmaceuticals Inc Stock Price, Fair Value and News

$41.03 
Market Closed as of 15 May 2026, 04:00 pm ET

74/100

APLS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

74/100

APLS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

APLS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

APLS Price Action

Last 30 days

0.4%

Last 90 days

89.1%

Trailing 12 Months

150.8%

APLS RSI Chart

APLS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

APLS Valuation

Market Cap

5.2B

Price/Earnings (Trailing)

39.38

Price/Sales (Trailing)

4.75

EV/EBITDA

27.31

Price/Free Cashflow

140.12

APLS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

APLS Fundamentals

APLS Revenue

Revenue (TTM)

1.1B

Rev. Growth (Yr)

60.85%

Rev. Growth (Qtr)

34.21%

APLS Earnings

Earnings (TTM)

133.3M

Earnings Growth (Yr)

120.23%

Earnings Growth (Qtr)

131.65%

APLS Profitability

EBT Margin

12.23%

Return on Equity

32.12%

Return on Assets

12.31%

Free Cashflow Yield

0.71%

APLS Investor Care

Shares Dilution (1Y)

1.80%

Diluted EPS (TTM)

1.07

APLS Alerts

  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20261.1B000
2025775.8M754.6M1.0B1.0B
2024524.1M628.8M715.2M781.4M
2023105.9M184.5M272.9M396.6M
202281.6M96.6M113.0M75.4M
20210189.3M127.9M66.6M
2020000250.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Apellis Pharmaceuticals Inc

APLS
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
 CEO
 WEBSITEapellis.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES767

Apellis Pharmaceuticals Inc Frequently Asked Questions

APLS is the stock ticker symbol of Apellis Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri May 15 2026, market cap of Apellis Pharmaceuticals Inc is 5.25 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri May 15 2026, APLS's PE ratio (Price to Earnings) is 39.38 and Price to Sales (PS) ratio is 4.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APLS PE ratio will change depending on the future growth rate expectations of investors.